Literature DB >> 19763593

The cuprizone animal model: new insights into an old story.

Markus Kipp1, Tim Clarner, Jon Dang, Sjef Copray, Cordian Beyer.   

Abstract

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease that affects the central nervous system and represents the most common neurological disorder in young adults in the Western hemisphere. There are several well-characterized experimental animal models that allow studying potential mechanisms of MS pathology. While experimental allergic encephalomyelitis is one of the most frequently used models to investigate MS pathology and therapeutic interventions, the cuprizone model reflects a toxic experimental model. Cuprizone-induced demyelination in animals is accepted for studying MS-related lesions and is characterized by degeneration of oligodendrocytes rather than by a direct attack on the myelin sheet. The present article reviews recent data concerning the cuprizone model and its relevance for MS. Particular focus is given to the concordance and difference between human MS patterns (types I-IV lesions) and cuprizone-induced histopathology, including a detailed description of the sensitive brain regions extending the observations to different white and grey matter structures. Similarities between pattern III lesions and cuprizone-induced demyelination and dissimilarities, such as inflamed blood vessels or the presence of CD3+ T cells, are outlined. We also aim to distinguish acute and chronic demyelination under cuprizone including processes such as spontaneous remyelination during acute demyelination. Finally, we point at strain and gender differences in this animal model and highlight the contribution of some growth factors and cytokines during and after cuprizone intoxication, including LIF, IGF-1, and PDGFalpha.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763593     DOI: 10.1007/s00401-009-0591-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  172 in total

1.  Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.

Authors:  Andrew J Steelman; Jeffrey P Thompson; Jianrong Li
Journal:  Neurosci Res       Date:  2011-10-12       Impact factor: 3.304

Review 2.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.

Authors:  Robert H Miller; Sharyl L Fyffe-Maricich
Journal:  Dis Model Mech       Date:  2010-07-20       Impact factor: 5.758

4.  IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination.

Authors:  Julian Zimmermann; Michael Emrich; Marius Krauthausen; Simon Saxe; Louisa Nitsch; Michael T Heneka; Iain L Campbell; Marcus Müller
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

5.  Neural Stem Cells of the Subventricular Zone Contribute to Neuroprotection of the Corpus Callosum after Cuprizone-Induced Demyelination.

Authors:  Erica Butti; Marco Bacigaluppi; Linda Chaabane; Francesca Ruffini; Elena Brambilla; Giulia Berera; Carolina Montonati; Angelo Quattrini; Gianvito Martino
Journal:  J Neurosci       Date:  2019-05-28       Impact factor: 6.167

6.  The Effect of Melatonin on Behavioral, Molecular, and Histopathological Changes in Cuprizone Model of Demyelination.

Authors:  Gelareh Vakilzadeh; Fariba Khodagholi; Tahereh Ghadiri; Amir Ghaemi; Farshid Noorbakhsh; Mohammad Sharifzadeh; Ali Gorji
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

7.  Epimedium flavonoids ameliorate neuropathological changes and increases IGF-1 expression in C57BL/6 mice exposed to cuprizone.

Authors:  Mengru Liang; Yongyan Chen; Li Zhang; Lin Li; Guangliang Chen; Linlin Yin
Journal:  Neurochem Res       Date:  2015-02-07       Impact factor: 3.996

8.  Cuprizone-induced oligodendrocyte loss and demyelination impairs recording performance of chronically implanted neural interfaces.

Authors:  Steven M Wellman; Kelly Guzman; Kevin C Stieger; Lauren E Brink; Sadhana Sridhar; Mitchell T Dubaniewicz; Lehong Li; Franca Cambi; Takashi D Y Kozai
Journal:  Biomaterials       Date:  2020-02-06       Impact factor: 12.479

9.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

10.  A cord blood monocyte-derived cell therapy product accelerates brain remyelination.

Authors:  Arjun Saha; Susan Buntz; Paula Scotland; Li Xu; Pamela Noeldner; Sachit Patel; Amy Wollish; Aruni Gunaratne; Tracy Gentry; Jesse Troy; Glenn K Matsushima; Joanne Kurtzberg; Andrew E Balber
Journal:  JCI Insight       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.